[go: up one dir, main page]

MA51113A - Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce) - Google Patents

Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce)

Info

Publication number
MA51113A
MA51113A MA051113A MA51113A MA51113A MA 51113 A MA51113 A MA 51113A MA 051113 A MA051113 A MA 051113A MA 51113 A MA51113 A MA 51113A MA 51113 A MA51113 A MA 51113A
Authority
MA
Morocco
Prior art keywords
adnce
closed
gene editing
modified dna
end modified
Prior art date
Application number
MA051113A
Other languages
English (en)
Inventor
Ozan Alkan
Douglas Kerr
Robert M Kotin
Phillip Samayoa
Matthew J Simmons
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA51113A publication Critical patent/MA51113A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051113A 2017-12-06 2018-12-06 Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce) MA51113A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595328P 2017-12-06 2017-12-06
US201762607069P 2017-12-18 2017-12-18

Publications (1)

Publication Number Publication Date
MA51113A true MA51113A (fr) 2020-10-14

Family

ID=66751200

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051113A MA51113A (fr) 2017-12-06 2018-12-06 Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce)

Country Status (14)

Country Link
US (1) US20220290186A1 (fr)
EP (1) EP3720952A4 (fr)
JP (2) JP2021505159A (fr)
KR (1) KR20200093635A (fr)
CN (1) CN111527200A (fr)
AU (1) AU2018378672A1 (fr)
BR (1) BR112020009858A2 (fr)
CA (1) CA3084185A1 (fr)
IL (1) IL274845A (fr)
MA (1) MA51113A (fr)
MX (1) MX2020005808A (fr)
PH (1) PH12020550771A1 (fr)
SG (2) SG11202005281XA (fr)
WO (1) WO2019113310A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (fr) 2014-01-08 2023-01-10 Bart Lipkens Dispositif d'acoustophorese avec double chambre acoustophoretique
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
EP3690046A2 (fr) * 2017-09-28 2020-08-05 Toolgen Incorporated Composition pour le traitement de l'hémophilie, comprenant un système crispr/cas ayant un potentiel de correction d'inversion du gène du facteur viii de coagulation
KR20200120649A (ko) * 2018-02-14 2020-10-21 제너레이션 바이오 컴퍼니 비-바이러스 dna 벡터 및 항체 및 융합 단백질 생산을 위한 이의 용도
CN109022389A (zh) * 2018-07-19 2018-12-18 陕西慧康生物科技有限责任公司 一种大肠杆菌表达人艾杜糖醛酸-2-硫酸酯酶的生产方法
CN119955796A (zh) 2018-08-09 2025-05-09 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
BR112021007102A2 (pt) * 2018-11-09 2021-08-03 Generation Bio Co. dna com extremidade fechada modificada (cedna) que compreende repetições terminais invertidas modificadas simétricas
SG11202111256XA (en) 2019-06-07 2021-11-29 Regeneron Pharma Non-human animals comprising a humanized albumin locus
EP4022074A4 (fr) * 2019-08-27 2023-11-15 The Trustees of Columbia University in the City of New York Exosomes modifiés pour une administration ciblée
US20220275400A1 (en) * 2019-08-30 2022-09-01 The Trustees Of Columbia University In The City Of New York Methods for scalable gene insertions
AU2021230546A1 (en) 2020-03-04 2022-10-13 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP2023520764A (ja) * 2020-03-24 2023-05-19 ジェネレーション バイオ カンパニー 第ｉｘ因子治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
JP2023526049A (ja) * 2020-05-13 2023-06-20 リソジェン Ｇｍ１ガングリオシド－シスおよび他の障害を処置するための組成物および方法
WO2022015856A1 (fr) * 2020-07-14 2022-01-20 The Regents Of The University Of California Compositions et méthodes de traitement d'une maladie rétinienne héréditaire
WO2022023284A1 (fr) * 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation
KR20230066615A (ko) * 2020-09-16 2023-05-16 제너레이션 바이오 컴퍼니 폐쇄형 dna 벡터 및 페닐알라닌 히드록실라아제(pah) 발현을 위한 이의 용도
US20230383311A1 (en) * 2020-09-16 2023-11-30 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing fviii therapeutics
US20250270545A1 (en) * 2020-09-29 2025-08-28 Albert-Ludwigs-Universitat Freiburg Rescue of recombinant adenoviruses by crispr/cas-mediated in vivo terminal resolution
CN112481262B (zh) * 2020-12-04 2022-08-19 中国农业科学院农业基因组研究所 一种基于CRISPR/Cas9基因编辑技术分析增强子细胞生物学功能的方法
CN112852880B (zh) * 2021-01-28 2022-12-06 中吉智药(南京)生物技术有限公司 一种基于诱导型昆虫细胞生产aav基因药物的方法
WO2022170059A1 (fr) 2021-02-05 2022-08-11 Christiana Care Health Services, Inc. Méthodes et compositions de réduction de l'expression et/ou de l'activité génique
CA3211687A1 (fr) * 2021-03-19 2022-09-22 Ozan ALKAN Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents therapeutiques de pfic
WO2022232117A1 (fr) * 2021-04-26 2022-11-03 University Of Massachusetts Édition génique in vivo des cellules souches hématopoïétiques à médiation directe par raav
EP4337177A1 (fr) * 2021-05-11 2024-03-20 Modernatx, Inc. Administration non virale d'adn pour expression prolongée de polypeptide in vivo
AU2022280952A1 (en) * 2021-05-28 2023-11-23 Beam Therapeutics Inc. Compositions and methods for the self-inactivation of base editors
WO2023283420A2 (fr) * 2021-07-09 2023-01-12 The Board Of Trustees Of The University Of Illinois Silençage génique thérapeutique avec crispr-cas13
EP4392443A1 (fr) * 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Gènes de facteur viii optimisés
CA3231677A1 (fr) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Procedes et compositions pour moduler un genome
EP4419677A4 (fr) 2021-10-18 2025-09-24 Flagship Pioneering Innovations Vii Llc Compositions d'adn et procédés associés
WO2024040222A1 (fr) 2022-08-19 2024-02-22 Generation Bio Co. Adn à extrémités fermées clivable (adnce) et ses procédés d'utilisation
US20240090481A1 (en) * 2022-09-16 2024-03-21 Joseph Fenton Lawler Trans-splicing methods and compositions for generation of single sex offspring
WO2024229153A2 (fr) * 2023-05-01 2024-11-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Systèmes et méthodes pour fournir un facteur viii thérapeutique à l'aide d'une administration d'acide nucléique médiée par ultrasons
WO2025064507A1 (fr) * 2023-09-19 2025-03-27 Poseida Therapeutics, Inc. Compositions et procédés d'intégration de vecteurs viraux
WO2025085119A2 (fr) * 2023-10-17 2025-04-24 Generation Bio Co. Compositions d'acide nucléique simple brin partiellement synthétiques et utilisations et procédés associés
WO2025083617A1 (fr) 2023-10-18 2025-04-24 Nanocell Therapeutics Holdings B.V. Procédés et compositions pour administrer une construction nucléique
WO2025106523A1 (fr) * 2023-11-14 2025-05-22 Nchroma Bio, Inc. Compositions et procédés de régulation épigénétique de l'expression de f8
WO2025106834A1 (fr) * 2023-11-17 2025-05-22 Temple University-Of The Commonwealth System Of Higher Education Système à plasmide unique pour recombinaison homologue médiée par crispr-cas9 améliorée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500434A1 (fr) * 2011-03-12 2012-09-19 Association Institut de Myologie Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique
EP2994531B1 (fr) * 2013-05-10 2018-03-28 Sangamo Therapeutics, Inc. Procédés et compositions d'apport pour génie génomique médié par nucléase
BR112016013201B1 (pt) * 2013-12-12 2023-01-31 The Broad Institute, Inc. Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
WO2015138620A1 (fr) * 2014-03-11 2015-09-17 University Of Washington Protéine nucléaire de restriction agissant lors de phases spécifiques du cycle cellulaire
WO2016154596A1 (fr) * 2015-03-25 2016-09-29 Editas Medicine, Inc. Procédés, compositions et constituants liés à crispr/cas
WO2016176191A1 (fr) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Système de vecteur aav double pour la correction médiée par crispr/cas9 d'une maladie humaine
WO2016205728A1 (fr) * 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Enregistrement d'événements cellulaires médié par crispr
PT3423110T (pt) * 2016-03-03 2021-11-09 Univ Massachusetts Adn em dúplex linear de extremidades fechadas para transferência génica não viral
WO2019051255A1 (fr) * 2017-09-08 2019-03-14 Generation Bio Co. Adn à extrémité fermée (cedna) modifié

Also Published As

Publication number Publication date
RU2020121128A (ru) 2022-01-11
WO2019113310A1 (fr) 2019-06-13
EP3720952A4 (fr) 2021-09-01
KR20200093635A (ko) 2020-08-05
SG10202012132WA (en) 2021-01-28
SG11202005281XA (en) 2020-07-29
JP2024003220A (ja) 2024-01-11
BR112020009858A2 (pt) 2020-11-17
CA3084185A1 (fr) 2019-06-13
CN111527200A (zh) 2020-08-11
AU2018378672A1 (en) 2020-07-09
US20220290186A1 (en) 2022-09-15
PH12020550771A1 (en) 2021-05-10
IL274845A (en) 2020-07-30
MX2020005808A (es) 2020-10-28
JP2021505159A (ja) 2021-02-18
EP3720952A1 (fr) 2020-10-14

Similar Documents

Publication Publication Date Title
MA51113A (fr) Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce)
MA52709A (fr) Administration d'adn
EP3500675A4 (fr) Méthodes d'édition de la méthylation de l'adn
IL281930A (en) Rna particles comprising polysarcosin
MA51915A (fr) Expression régulée de transgènes à l'aide de vecteurs adn à extrémités fermées (cedna)
EP3450569A4 (fr) Procédé d'amplification d'adn
MA50100A (fr) Adn à extrémité fermée (cedna) modifié
MA71572A (fr) Variants d'arn polymérase
EP3877521A4 (fr) Formulations de nanoparticules lipidiques
EP3382018A4 (fr) Kit d'édition de méthylation d'adn et procédé d'édition de méthylation d'adn
MA50942A (fr) Protéines de liaison à l'adn modifiées
EP3494210A4 (fr) Pronostiqueur de mortalité basé sur la méthylation de l'adn
EP3501008A4 (fr) Opérations à l'aide des données volumétriques éparses
EP3728575A4 (fr) Systèmes cas12b, procédés et compositions pour l'édition de base d'adn ciblée
EP3381947A4 (fr) Mutant d'adn polymérase
EP3642353A4 (fr) Évaluation du risque de complication d'une greffe avec l'adn acellulaire total
EP3512535A4 (fr) Déméthylation d'adn améliorée ciblée
EP3368279A4 (fr) Manipulation de pièce à l'aide de points de manipulation imprimés
EP3408389A4 (fr) Isotachophorèse destinée à la purification d'acides nucléiques
EP3440205A4 (fr) Diagnostics non invasifs par séquençage d'adn acellulaire 5-hydroxyméthylé
EP3433382A4 (fr) Spike-ins d'acides nucléiques synthétiques
EP3874510A4 (fr) Estimation de phénotypes à l'aide de l'adn, du pedigree et de données historiques
MA53548A (fr) Formulations antiparasitaires de goût agréable
EP3508587A4 (fr) Procédé de séquençage d'adn
IL282456A (en) Engineered dna polymerase variants